DNA 시퀀싱 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 기술별, 워크플로우별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

DNA Sequencing Market Size, Share & Trends Analysis Report By Product & Service, By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,257,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,645,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,420,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

DNA 시퀀싱 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 DNA 시퀀싱 시장 규모는 2024년부터 2030년까지 21.65%의 연평균 복합 성장률(CAGR)로 확대되어 2030년에는 482억 2,000만 달러에 달할 것으로 예상됩니다.

인공지능(AI)의 도입은 임상 현장에서 게놈 데이터의 유용성을 높이고 게놈 데이터 분석의 발전에 새로운 지평을 열어줄 것입니다.2020년 5월, 엔비디아(Nvidia Corporation)는 코로나19 연구 활동을 지원하기 위해 새로운 AI 도구, 게놈 시퀀싱 소프트웨어, 음성 인식 기술을 개발했다, 게놈 시퀀싱 소프트웨어, 음성 인식 기술을 개발했습니다. 이러한 AI는 임상 진단에서 변종에 대한 주석과 우선순위를 지정하는 것을 가속화하여 시장을 주도할 것입니다.

인간 게놈 프로젝트가 완료된 이후 DNA 염기서열 분석 비용이 급격히 하락하여 한 사람의 게놈을 해독하는 데 드는 비용은 10년 전 약 5만 달러에서 현재 가장 큰 게놈 센터의 경우 600달러에 육박하고 있습니다. 최근에는 2020년 2월 BGI가 게놈 시퀀싱 비용을 100달러로 낮출 것이라고 주장하고 있습니다. 이를 통해 산전 검사, 암 검진, 조사 연구에 대한 이용이 확대될 것으로 예상됩니다.

비용의 대폭적인 하락과 자금 조달 가능성이 결합되어 여러 스타트업이 시장에 진입하고 있습니다. 예를 들어, 2020년 1월 미국 스타트업 옴니옴멈(Omniome)은 유전자 시퀀싱 플랫폼의 후기 제품 개발 및 제품 출시를 가속화하기 위해 6,000만 달러의 시리즈 C 펀딩을 유치하여 시장 확대에 박차를 가하고 있습니다.

DNA 시퀀싱 시장 보고서 하이라이트

• 컨설팅 서비스, 교육 과정, 고객 지원과 함께 저렴한 가격으로 서비스를 이용할 수 있게 된 것이 예측 기간 동안 서비스 분야를 가장 빠른 성장률로 견인할 것으로 예상됩니다.
• 새로운 시스템 출시로 인한 3세대 기술의 지속적인 기술 발전이 이 부문을 유리한 CAGR로 견인할 것으로 예상됩니다.
• 예를 들어, 2019년 7월 Oxford Nanopore는 자사의 GridION X5 시스템의 성능을 향상시키는 벤치탑, 유연한 NGS 및 데이터 분석 장비인 GridION Mk1을 출시하였습니다.
• 워크플로우에 따르면, 데이터 분석 단계는 예측 기간 동안 상당한 CAGR을 기록할 것으로 예상됩니다.
• HTS-flow가 탑재된 워크플로우 관리 시스템의 등장은 실험실 관리 시스템에서 데이터를 가져와 간단한 GUI로 데이터 분석을 관리함으로써 데이터 분석 워크플로우를 효율화합니다.
• 이러한 기술은 암 진단 및 치료제 개발을 위해 유전자 변이를 시퀀싱하고 분류하기 위해 종양학 분야에서 널리 받아들여지고 있습니다.
• 전 세계 암 환자 증가가 종양학 수요를 주도하고 있습니다. 미국에서는 2020년에 약 180만 명의 암 환자가 새로 발생할 것으로 추정됩니다.
• 예측 기간 동안 임상 연구 분야가 가장 빠른 성장률을 보일 것으로 예상되며, 병원 및 클리닉이 그 뒤를 이을 것으로 예상됩니다.
• 코로나19 진단을 위해 병원 및 진단센터에서 NGS 기반 진단 검사에 대한 접근성을 확대하기 위해 기업 및 정부 기관이 취하는 노력은 병원 및 클리닉 부문을 유리한 속도로 견인할 것으로 예상됩니다.
• 아시아태평양에서는 이러한 도구를 사용하는 수많은 연구 프로그램 덕분에 예측 기간 동안 가장 높은 CAGR로 시장이 발전할 것으로 예상됩니다.
• 예를 들어, 2019년 10월 싱가포르 과학기술연구청 게놈연구소 연구진은 희귀질환 진단을 지원하기 위해 아시아 최대 규모의 유전자 데이터베이스를 구축했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 DNA 시퀀싱 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조적인 시장 전망.
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• DNA 시퀀싱 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 DNA 시퀀싱 시장 : 제품 및 서비스 추정·동향 분석

• 제품 및 서비스 시장 점유율, 2023년 및 2030년
• 시장 규모, 예측, 동향 분석, 2018-2030년
  • 소모품
  • 기구
  • 서비스

제5장 DNA 시퀀싱 시장 : 기술 추정·동향 분석

• 테크놀러지 시장 점유율, 2023년과 2030년
• 시장 규모, 예측, 동향 분석, 2018-2030년
  • Sanger sequencing
  • NGS
  • 제3세대 시퀀싱

제6장 DNA 시퀀싱 시장 : 워크플로우 추정·동향 분석

• 워크플로우 시장 점유율, 2023년과 2030년
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • Pre-sequencing
  • 시퀀싱
  • 데이터 분석

제7장 DNA 시퀀싱 시장 : 용도 추정·동향 분석

• 용도 시장 점유율, 2023년과 2030년
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 종양학
  • 생식건강
  • 임상시험
  • Agrigenomics & Forensics
  • HLA 타이핑
  • Metagenomics, Epidemiology, & Drug Development
  • 소비자 유전체학
  • 기타

제8장 DNA 시퀀싱 시장 : 최종 용도 추정·동향 분석

• 최종 용도 시장 점유율, 2023년 및 2030년
• 시장 규모, 예측 및 동향 분석, 2018-2030년

제9장 DNA 시퀀싱 시장 : 지역 추정·동향 분석

• 지역 시장 점유율 분석, 2023년 및 2030년
• 북미
  • 북미 시장 추산·예측(2018-2030년)
  • 미국
  • 캐나다
• 유럽
  • 유럽 시장 추산·예측(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 아시아태평양 시장 추산·예측(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 라틴아메리카 시장 추산·예측(2018-2030년)
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카(MEA) 시장 추산·예측(2018-2030년)
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 예측 기간 동안 연평균 복합 성장률(CAGR)
• 전략 매핑
• 기업 시장 현황 분석, 2023년
• 기업 개요/리스트 표
  • Thermo Fisher Scientific, Inc
  • Agilent Technology
  • Illumina, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Oxford Nanopore Technologies plc.
  • Macrogen, Inc.
  • PerkinElmer Genomics
  • PacBio
  • BGI
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics
  • PierianDx
  • Partek Incorporated
  • Eurofins Scientific

LSH

영문 목차

영문목차

DNA Sequencing Market Growth & Trends:

The global DNA sequencing market size is expected to reach USD 48.22 billion by 2030, expanding at a CAGR of 21.65% from 2024 to 2030, according to a new report by Grand View Research, Inc. The incorporation of Artificial Intelligence (AI) has increased the utility of genomic data in clinical practices and thus creates a new frontier in the advancement of genomic data analysis. In May 2020, Nvidia Corporation developed new AI tools, genomic sequencing software, and speech recognition technologies to aid the COVID-19 research efforts. Thus, AI accelerates the variant annotation and prioritization in the clinical diagnosis, which drives the market.

Since the completion of the Human Genome Project, the DNA sequencing cost has declined precipitously. The cost of decoding one person's genome was around USD 50,000 a decade ago and currently has reached nearly USD 600 in the largest genomic centers. Recently, in February 2020, BGI claimed to reduce the cost to sequence the genome to USD 100. This is expected to expand the use of this technology for prenatal tests, cancer screening, and research studies.

With a significant decrease in cost coupled with the availability of funding, several start-ups have entered the market. For instance, in January 2020, Omniome, a startup firm from the U.S., raised USD 60.0 million in Series C financing to speed up the late-stage product development and product launch of its genetic sequencing platform, which consequently fuels market progression.

DNA Sequencing Market Report Highlights:

• Rise in the availability of services at affordable prices along with consulting services, training courses, and customer support are anticipated to drive the services segment at the fastest growth rate over the forecast period
• Constant technological advancements in third-generation techniques with the launch of new systems are expected to drive this segment at a lucrative CAGR
• For instance, in July 2019, Oxford Nanopore launched GridION Mk1, a benchtop, flexible NGS, data analysis device that improves the performance of the company's GridION X5 system
• On the basis of workflow, the data analysis step is anticipated to register a considerable CAGR throughout the forecast period
• The advent of workflow management systems with HTS-flow retrieves data from laboratory management systems and manages data analysis through a simple graphical user interface, subsequently streamlining the data analysis workflow
• These technologies are widely accepted in the oncology field to sequence and catalog gene mutations for the development of cancer diagnostic and therapeutics
• A rise in cancer cases globally is driving demand for oncology. It is estimated that there would be nearly 1.8 million new cancer cases in 2020 in the U.S.
• The clinical research segment is projected to witness the fastest growth rate over the forecast period, followed by hospitals and clinics
• Efforts undertaken by companies and government agencies to broaden the accessibility for NGS-based diagnostic tests in the hospitals and diagnostic centers for COVID-19 diagnosis is anticipated to drive the hospitals and clinics segment at a lucrative pace
• In Asia Pacific, the market is expected to progress with the highest CAGR over the forecast period owing to numerous research programs that involve the usage of these tools
• For instance, in October 2019, researchers from the Agency for Science, Technology and Research's Genome Institute of Singapore created the largest genetic databank of Asian populations to support the diagnosis of rare diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Technology
  • 1.2.3. Workflow
  • 1.2.4. Application
  • 1.2.5. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. DNA Sequencing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in sequencing techniques
    • 3.2.1.2. Rising interest in genomics research and personalized medicine
    • 3.2.1.3. Increasing applications of DNA sequencing in clinical diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Data storage and management challenges
    • 3.2.2.2. Ethical and privacy concerns related to the use of sequencing technologies.
• 3.3. DNA Sequencing Market Analysis Tools
  • 3.3.1. Industry analysis - Porter's
  • 3.3.2. PESTEL analysis
  • 3.3.3. COVID-19 impact analysis

Chapter 4. DNA Sequencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Market Share, 2023 & 2030
• 4.2. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 4.2.1. Consumables
    • 4.2.1.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.2.3. Services
    • 4.2.3.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNA Sequencing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2023 & 2030
• 5.2. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 5.2.1. Sanger sequencing
    • 5.2.1.1. Sanger sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.2.2. Next-generation sequencing (NGS)
    • 5.2.2.1. Next-generation sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2.2. Whole genome sequencing (WGS)
    • 5.2.2.2.1. Whole genome sequencing (WGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2.3. Whole exome sequencing (WES)
    • 5.2.2.3.1. Whole exome sequencing (WES) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2.4. Targeted sequencing & resequencing
    • 5.2.2.4.1. Targeted sequencing & resequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.2.3. Third generation dna sequencing
    • 5.2.3.1. Third generation dna sequencing market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3.2. Single-molecule real-time sequencing (SMRT)
    • 5.2.3.2.1. Single-molecule real-time sequencing (SMRT) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3.3. Nanopore sequencing
    • 5.2.3.3.1. Nanopore sequencing market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNA Sequencing Market: Workflow Estimates & Trend Analysis

• 6.1. Workflow Market Share, 2023 & 2030
• 6.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.2.1. Pre-sequencing
    • 6.2.1.1. Pre-sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.2.2. Sequencing
    • 6.2.2.1. Sequencing Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.2.3. Data Analysis
    • 6.2.3.1. Data analysis Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNA Sequencing Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2023 & 2030
• 7.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.2.1. Oncology
    • 7.2.1.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.2. Reproductive Health
    • 7.2.2.1. Reproductive health market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.3. Clinical Investigation
    • 7.2.3.1. Clinical investigation Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.4. Agrigenomics & Forensics
    • 7.2.4.1. Agrigenomics & forensics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.5. HLA Typing/Immune System Monitoring
    • 7.2.5.1. HLA Typing/Immune System Monitoring market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.6. Metagenomics, Epidemiology, & Drug Development
    • 7.2.6.1. Metagenomics, epidemiology, & drug development market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.7. Consumer Genomics
    • 7.2.7.1. Consumer genomics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.8. Others
    • 7.2.8.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. DNA Sequencing Market: End-use Estimates & Trend Analysis

• 8.1. End-use Market Share, 2023 & 2030
• 8.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.2.1. Academic Research
    • 8.2.1.1. Academic research market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.2. Clinical Research
    • 8.2.2.1. Clinical research market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.3. Hospitals & Clinics
    • 8.2.3.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.4. Pharmaceutical & Biotechnology Companies
    • 8.2.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.5. Others
    • 8.2.5.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. DNA Sequencing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. North America
  • 9.2.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. Regulatory framework
    • 9.2.2.3. Target disease prevalence
    • 9.2.2.4. Competitive scenario
    • 9.2.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Regulatory framework
    • 9.2.3.3. Target disease prevalence
    • 9.2.3.4. Competitive scenario
    • 9.2.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Target disease prevalence
    • 9.3.2.4. Competitive scenario
    • 9.3.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Target disease prevalence
    • 9.3.3.4. Competitive scenario
    • 9.3.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Target disease prevalence
    • 9.3.4.4. Competitive scenario
    • 9.3.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Regulatory framework
    • 9.3.5.3. Target disease prevalence
    • 9.3.5.4. Competitive scenario
    • 9.3.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Regulatory framework
    • 9.3.6.3. Target disease prevalence k
    • 9.3.6.4. Competitive scenario
    • 9.3.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.7. Norway
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Regulatory framework
    • 9.3.7.3. Target disease prevalence
    • 9.3.7.4. Competitive scenario
    • 9.3.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Regulatory framework
    • 9.3.8.3. Target disease prevalence
    • 9.3.8.4. Competitive scenario
    • 9.3.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.9. Denmark
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Regulatory framework
    • 9.3.9.3. Target disease prevalence
    • 9.3.9.4. Competitive scenario
    • 9.3.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Target disease prevalence
    • 9.4.4.4. Competitive scenario
    • 9.4.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Target disease prevalence
    • 9.4.5.4. Competitive scenario
    • 9.4.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Target disease prevalence
    • 9.4.6.4. Competitive scenario
    • 9.4.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Target disease prevalence
    • 9.4.7.4. Competitive scenario
    • 9.4.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Argentina
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Target disease prevalence
    • 9.6.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Target disease prevalence
    • 9.6.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2023
• 10.4. Company Profiles/Listing
  • 10.4.1. Thermo Fisher Scientific, Inc
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product & service benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Agilent Technology
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product & service benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Illumina, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product & service benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. QIAGEN
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product & service benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. F. Hoffmann-La Roche Ltd.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product & service benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Oxford Nanopore Technologies plc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product & service benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Macrogen, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product & service benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. PerkinElmer Genomics
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product & service benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. PacBio
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product & service benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. BGI
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product & service benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Bio-Rad Laboratories, Inc.
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product & service benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. Myriad Genetics
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product & service benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. PierianDx
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product & service benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Partek Incorporated
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product & service benchmarking
    • 10.4.14.4. Strategic initiatives
  • 10.4.15. Eurofins Scientific
    • 10.4.15.1. Company overview
    • 10.4.15.2. Financial performance
    • 10.4.15.3. Product & service benchmarking
    • 10.4.15.4. Strategic initiatives

관련자료